ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

First Androgel Trial Begins in Chicago

U.S. courtroom with flag

The first of thousands of lawsuits over the dangers of taking testosterone-boosting drugs has gone to trial in a federal court in Chicago.

Jeffrey Konrad, 56, of Tennessee says he suffered a heart attack in 2010 after taking AndroGel for three months. He is suing drug maker AbbVie, accusing the pharma giant of aggressively marketing the drug by convincing thousands of men and their doctors they had a made-up condition called “Low T,” or low testosterone, when they were really just getting older.

The nearly 4,000 cases, consolidated as multidistrict litigation, also include lawsuits against defendants Besins, Eli Lilly and GlaxoSmithKline by men who say they suffered health problems as a result of taking testosterone drugs. In addition to the federal lawsuits, the companies also face more than 200 claims in various state courts.

Konrad’s is one of seven selected to serve as bellwethers to determine various issues in all the cases. The trial in his case started Monday, June 5.

Before the trial, U.S. District Judge Matthew Kennelly dismissed some of the claims against Abbvie relating to alleged design defects, but allowed claims related to off-label marketing to proceed.

Lawsuit: Risks Ignored, Benefits Overstated

According to Konrad’s lawsuit, AbbVie “promoted and marketed testosterone replacement therapy to physicians as a lifestyle drug that could treat a variety of symptoms caused by the normal aging process in males, including: erectile dysfunction; loss of libido; loss of athleticism; loss of muscle mass; fatigue; and mood swings. Defendants overstated the benefits of testosterone as a treatment for lifestyle changes associated with the aging process despite the fact that the drug was never FDA approved for these uses.”

At the same time, the lawsuit says, AbbVie “purposely downplayed, understated, and outright ignored the health hazards and risks associated with using AndroGel.”

The complaint accuses AbbVie of negligent misrepresentation and fraud.

As attention to the dangers rose and the U.S. Food and Drug Administration required a warning that testosterone supplements may increase the risk of heart attack and stroke, AbbVie took a hit when AndroGel sales began to slip.

Once topping $1 billion annually — $1.15 billion in 2012 — the drug generated $675 million in 2016 sales, according to AbbVie’s annual report. Sales sank by $240 million between 2014 and 2015, the year the FDA required the warning.

Researchers Spot Heart-Attack Risk

In 2014, researchers found that taking testosterone doubled the risk of heart attack for men over 65 and almost tripled the risk in younger men with a history of heart disease.

According to court pleadings and a transcript of the final pretrial hearing in the Konrad case, AbbVie lawyers plan to argue, in part, that AbbVie acted appropriately when Konrad received his prescriptions, given what was known at the time. The company also sought to limit evidence about its marketing of AndroGel to the specific advertisements and materials seen by Konrad and his doctor.

AbbVie maintains that its marketing of AndroGel was protected by the First Amendment, and that claims about the drug not being safe are preempted by Food and Drug regulations.

Konrad argues in court filings that the risks of taking testosterone were known as far back as the late 1970s and that when the FDA approved AndroGel for marketing and use in the U.S. in 2000, it limited its approval to patients with a condition called hypogonadism, a specific condition of the endocrine system which in men can involve severely diminished or no testosterone.

AbbVie and its predecessor, Abbott, the plaintiff argues, marketed the drug beyond that, charting a course to grow the market from 150,000 men in 2000 to as many as 4 million men the following year. By 2003, the market had increased to up to 20 million men.

Quiz Drafted Quickly

As part of the marketing campaign, the company used a quiz developed by a medical school professor at the behest of another pharmaceutical company in exchange for a $40,000 grant to the St. Louis School of Medicine.

According to Konrad’s lawsuit, the professor, Dr. John Morley, drafted the quiz in 20 minutes in the bathroom, scribbling the questions on toilet paper and giving it to his secretary the next day to type. Morley, the lawsuit says, admits it’s a “crappy questionnaire”, and yet it’s used on AbbVie’s marketing website.

“AbbVie’s marketing knew no bounds,” Konrad’s lawyer argued in a court filing, “as it spent fifteen years influencing beliefs in the medical community and fears and desires in the aging male consumer.” AbbVie continued to pursue this strategy, the plaintiff maintains, in spite of the fact that the FDA put it on notice that its claims were misleading and in the absence of studies saying it was safe and effective.

One expert retained by Konrad says there was evidence of a “causal association” between AndroGel and heart attacks as early as 2007, a court filing said. But Abbvie didn’t warn doctors and failed to conduct large-scale studies to further investigate.

Elaine Silvestrini
Written By Elaine Silvestrini Writer

Elaine Silvestrini is an award-winning journalist with 30 years of experience covering state and federal court systems. She joined Drugwatch in 2017. Her coverage for Drugwatch has been cited in the CDC’s Public Health Law News and the USA Today Network. Some of her qualifications include:

  • Centers for Disease Control and Prevention certificates in Health Literacy
  • Experience as an assistant investigator for the Federal Public Defender
  • Loyola Law School Journalist Law School Fellowship

9 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Szabo, L. (2015, March 3). FDA warns that Testosterone increases heart risk. Retrieved
  2. Bloomberg. (2017, June 5). AbbVie’s testosterone gel under microscope as first trial begins. Retrieved
  3. AbbVie. (2017). 2016 Annual Report on Form 10-K and 2017 Proxy Statement. Retrieved
  4. AbbVie. (2013, January 30). AbbVie Issues Inaugural Full-Year Outlook for 2013. Retrieved
  5. Jeffrey Konrad and Jana Konrad v. AbbVie Inc., and Abbott Laboratories Inc. (2015, January 29). Complaint filed in U.S. District Court for the Northern District of Illinois Eastern Division.
  6. In re: Testosterone Replacement Therapy Products Liability Litigation. (2016, November 2). AbbVie Defendants’ Notice of Affirmative Defenses. United States District Court Northern District of Illinois.
  7. In re: Testosterone Replacement Therapy Products Liability Litigation. (2017, May 27). Plaintiffs’ Proffer Regarding The Case Against AbbVie For Punitive Liability.
  8. In re: Testosterone Replacement Therapy Products Liability Litigation. (2017, May 29). Defendants’ Response to Plaintiffs’ Proffer Regarding The Case Against Abbvie For Punitive Liability.
  9. In re: Testosterone Replacement Therapy Products Liability Litigation. (2017, May 30) Exhibit 1. Transcript of Proceedings - Pretrial Conference Before The Honorable Matthew F. Kennelly.
View All Sources
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's sponsors support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our sponsors page.

(888) 645-1617